Azapride is the azide derivative of the dopamine antagonist clebopride synthesized in order to label dopamine receptors.[1][2] It is an irreversible dopamine antagonist.[2]

Azapride
Clinical data
Other namesAzidoclebopride
ATC code
  • None
Identifiers
  • 4-Azido-5-chloro-2-methoxy-N-[1-(phenylmethyl)piperidin-4-yl]benzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22ClN5O2
Molar mass399.88 g·mol−1
3D model (JSmol)
  • Clc1cc(c(OC)cc1/N=[N+]=[N-])C(=O)NC3CCN(Cc2ccccc2)CC3
  • InChI=1S/C20H22ClN5O2/c1-28-19-12-18(24-25-22)17(21)11-16(19)20(27)23-15-7-9-26(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13H2,1H3,(H,23,27) checkY
  • Key:CKKHIIXHAWWTNP-UHFFFAOYSA-N checkY
  (verify)

References

edit
  1. ^ Niznik HB, Guan JH, Neumeyer JL, Seeman P (February 1985). "A photoaffinity ligand for dopamine D2 receptors: azidoclebopride". Molecular Pharmacology. 27 (2): 193–9. PMID 3969068.
  2. ^ a b Wouters W, Van Dun J, Laduron PM (December 1984). "Photoaffinity labelling of dopamine receptors. Synthesis and binding characteristics of azapride". European Journal of Biochemistry. 145 (2): 273–8. doi:10.1111/j.1432-1033.1984.tb08548.x. PMID 6548707.